The efficacy and safety of thermal ablation for patients with lung malignancy: a meta-analysis of 12 studies in China

Table 1 Characteristics of included studies

Year of publication	First author	Study location	Type of lung cancer	Stage of lung cancer	Previous treatment naive?	Randomized?	Type of ablation	Sample size	Average age, year	Average follow up, month
2011	Hua Shen [9]	China	NSCLC	IIIb/IV	No	Yes	RFA	80	59	NA
2014	Sheng Li [10]	China	Metastases	NA	Yes	No	RFA	61	≤ 70	57
2015	Zhigang Wei [11]	China	NSCLC	IIIb/IV	Yes	No	MWA	74	59	21
2016	Zilin Zhao [12]	China	NSCLC	II/IIIa	Yes	Yes	MWA	96	57	39
2016	Shuo Yu [13]	China	NSCLC	III/IV	NA	Yes	RFA	57	58	NA
2019	Wen-Hui Yang [14]	China	NSCLC	IIIb/IV	Yes	No	RFA	93	64	11
2019	Chunhai Li [15]	China	NSCLC	IV	Yes	No	MWA	49	> 60	NA
2020	Zhigang Wei [16]	China	NSCLC	IIIb/IV	Yes	Yes	MWA	293	59	13
2020	Ying-Qing Zhang [17]	China	NSCLC	IIIb/IV	Yes	Yes	MWA	90	69	36
2021	Feng Xu [18]	China	Lung cancer	I-IV	NA	No	RFA	256	48	16
2021	Yuqing Shan [7]	China	NSCLC	IV	Yes	Yes	MWA	67	61	NA
2021	Kan Feng [19]	China	Lung cancer	IIIb/IV	NA	No	MWA	66	47	NA

NSCLC non-small cell lung cancer, NA not available, RFA radiofrequency ablation, MWA microwave ablation

ISSN: 1749-8090